Etelcalcetide Reverses Cardiac Dysfunction in Mice with Chronic Hyperphosphatemia

Chronic kidney disease-mineral and bone disorder represents a complex systemic failure of homeostasis that significantly elevates the risk of cardiovascular morbidity and mortality [1, 2]. While clinicians traditionally focused on exogenous calcium loading to manage secondary hyperparathyroidism, contemporary management emphasizes a neutral calcium balance to avoid accelerating vascular calcification [3]. Calcimimetics, such as the intravenous agent etelcalcetide, have become a cornerstone of therapy by increasing the sensitivity of the calcium-sensing receptor (a protein on parathyroid cells that monitors extracellular calcium levels) to suppress parathyroid hormone without the hypercalcemic risk associated with vitamin D receptor activators [4, 5]. Despite improved biochemical control, the specific impact of these agents on cardiac morphology remains a subject of active clinical investigation [6]. A new study in a murine model of chronic phosphate overload (2.0 percent diet) now provides a detailed mechanistic analysis of how etelcalcetide restores systolic function and reduces fibrosis by activating the calcium-sensing receptor/cyclic adenosine monophosphate/phospholamban/Serca2a signaling pathway within the myocardium [7]. For practicing nephrologists and cardiologists, this suggests that calcimimetics may offer direct cardioprotective benefits beyond their systemic hormonal effects.